Introduction {#S1}
============

Influenza virus is responsible for annual epidemic infection around the world causing severe morbidity, mostly among elderly, children, and people with chronic pulmonary disease. Influenza virus has the capacity to interact with various cell populations in the lungs that contribute to the earliest wave of production of type 1 interferon and inflammatory cytokines which in turn will trigger local and systemic responses against the virus. When not well controlled, virally infected cells can be extensively targeted by innate cells that may result in an excessive production of inflammatory mediators and an enhanced pulmonary inflammation and lung illness ([@B1]--[@B3]).

Regulatory T cells (Treg) are a subpopulation of CD4^+^ T cells that have been identified as suppressors of immune responses and inflammation ([@B4]). Tregs are recognized as CD4^+^ CD25^+^ T cells which specifically express the transcription factor FoxP3 ([@B5], [@B6]). They play a central role in the maintenance of immunological tolerance and are also known to maintain self-tolerance and prevent autoimmune and chronic inflammatory diseases ([@B7]--[@B9]). Suppressive functions of Treg cells are known to be associated with TGF-β inhibitory effects and critical for immune homeostasis ([@B10], [@B11]). The role of TGF-β in controlling T cells functions and immune responses has been extensively studied by acting as a key regulator of the signaling pathway that promotes the generation of Tregs from CD4^+^ CD25^−^ precursors ([@B12]). It was proposed that Tregs can control immune balance during viral infection and to limit the extent of tissue damage that occurs in the course of infection ([@B13]--[@B15]). For example, Tregs appear essential to clear influenza virus infection in neonatal mice ([@B16]), as their depletion results in enhanced lung inflammatory response to IAV infection. In line with these observations, it was also demonstrated that Tregs contribute to the resolution of lung inflammation after influenza virus infection ([@B17]). Conversely, other studies reported that Tregs have little effects on severity of disease after infection ([@B18], [@B19]). In fact, it was shown that administration of Treg neutralizing antibodies to infected mice has no significant effects on body weight loss, mortality, and viral clearance, suggesting that this cell population has a limited role in controlling IAV infection.

Early excessive neutrophil infiltration to the lung is a well-characterized symptom of IAV infection ([@B20]--[@B22]). Th17 cells through IL-17A production can mobilize neutrophils to the site of inflammation ([@B23], [@B24]). A prolonged presence of Th17 and neutrophils could thus impair tissue integrity. Since the balance between Tregs and Th17 cells is essential for homeostasis, a loss of this delicate balance may result in deleterious effect on an efficient control of inflammation during IAV infection ([@B25]--[@B27]).

Recognition of pathogens by host innate sensors is a prerequisite for the initiation of immune response. While initially reported to recognize bacterial component such as bacterial peptidoglycan-derived muramyl dipeptide (MDP) ([@B28], [@B29]), nucleotide-binding oligomerization domain 2 (NOD2), a member of the nucleotide-binding oligomerization domain-like receptors, also has the capacity to bind ssRNA from various viruses including influenza A virus (IAV) ([@B30]). Importance of this receptor in controlling influenza infection was supported in *Nod2*^−/−^ mice, which were found to be hypersusceptible to infection, and showed enhanced pulmonary airway obstruction ([@B30], [@B31]). Previous work from our laboratory has demonstrated that treatment of influenza virus-infected mice with MDP induces the production of type I interferon, reduces lung viral loads and inflammation, and improves pulmonary function ([@B32]). While the mechanisms associated with NOD2 in the control of inflammation remain to be identified, a previous study has suggested a functional relevance of NOD2 in Treg biology ([@B33]). Indeed, polymorphism of NOD2 receptor that characterizes patients with Crohn's disease has been associated with a deficiency in Treg cells levels.

In the present study, we demonstrate that treatment of IAV-infected mice with NOD2 agonist, MDP, significantly increases Treg cells mobilization to the lungs. Such presence of Tregs in lungs of infected mice correlates with a reduced number of Th17 cells and infiltrated neutrophils. Furthermore, functional depletion of peripheral blood monocytes with clodronate liposome administration, results in an impaired mobilization of Treg cells to the lungs, suggesting the essential role of monocytes, and predominantly Ly6C^low^ monocytes in this process. Together, our results shed light on innate mechanisms involved in the NOD2-mediated regulation of lung inflammation in the course of IAV infection.

Materials and Methods {#S2}
=====================

Ethics Statement {#S2-1}
----------------

This study was carried out in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the Canadian Council on Animal Care. All protocols were approved by the Committee on the Ethics of Animal Experiments of Université Laval (Approval Number: 15-109-2).

Mice {#S2-2}
----

The 4- to 6-week-old C57Bl/6 wild-type (WT) mice were obtained from Charles River (St-Constant, QC, Canada) and NOD2-deficient mice (*Nod2^−/−^*) from Jackson Laboratory. All mouse colonies and littermates were housed in a controlled environment and a specific pathogen-free animal facility at the Centre de Recherche du CHU de Quebec, Laval University.

Viral Infections {#S2-3}
----------------

Infections were achieved using Influenza virus (IAV) strain A/Puerto Rico/8/34 (H1N1). IAV was disseminated and extracted from Madin-Darby canine kidney (MDCK) cells. MDCK cells were titrated using standard plaque assay as reported ([@B34]). Animals were infected intranasally (i.n.), at day 0 of the protocols, with a sublethal dose of IAV \[50 plaque forming unit (PFU)\]. We daily assessed the general health of the animal by monitoring their physical appearance, body weight and temperature.

*In Vivo* Treatments {#S2-4}
--------------------

MDP (Invivogen) was diluted in saline (0.9% p/v) and intravenously (i.v.) injected in the tail vein of mice at 10 mg/kg. Treatments started one day after IAV-infection. Control mice were injected with saline (0.9% p/v) (placebo). Mice were treated daily and were sacrificed at indicated times.

Depletion of Blood Monocytes {#S2-5}
----------------------------

Mouse blood monocytes were depleted using dichloromethylene-biphosphonate (clodronate)-loaded liposomes (Clodronate liposomes, Amsterdam, Netherlands) as previously described ([@B35], [@B36]). Clodronate-loaded liposomes (200 µl) were injected in mice tail vein, 24 h prior to influenza virus infection, unless otherwise indicated. Control animals received PBS-loaded liposomes. Monocytes depletion efficiency was monitored at indicated times by flow cytometry.

Flow Cytometry Analysis {#S2-6}
-----------------------

Single-cell suspensions obtained from blood or collagenase and DNase-digested lungs were first incubated with anti-CD16/32 (clone 93 BioLegend, San Diego, CA, USA) to block non-specific antibody interaction with Fc receptors. Fixable viability dye eFluor^®^450 (eBioscience, San Diego, CA, USA) was used to identify live cells following cellular fixation/permeabilization. For intracellular cytokine staining, cells were first stimulated for 5 h at 37°C with 50 ng/ml PMA, 1 µg/ml ionomycin (Sigma-Aldrich, St. Louis, MO, USA) and with 10 µg/ml of GolgiStop (BD Biosciences, San Diego, CA, USA). Tregs cells were identified using anti-CD4 (clone RM4-5; BioLegend San Diego, CA, USA), anti-CD25 (clone PC61; BioLegend San Diego, CA, USA), and anti-FoxP3 (clone FJK-16s; eBioscience, San Diego, CA, USA). Th17 cells were identified using IL-17A (clone eBio17B7 eBioscience, San Diego, CA, USA), and anti-CD4. Blood monocytes and neutrophils were identified using anti-CD45 (clone 30F11; BD Biosciences, San Diego, CA, USA), anti-CD115 (clone AFS98; BioLegend, San Diego, CA, USA), anti-Ly6G (clone 1A8; BD Biosciences), anti-CD11b (clone M1/70; BD Biosciences), and anti-Ly6C (clone HK1.4; BioLegend, San Diego, CA, USA). Flow cytometry was performed using BD LSR II (BD Biosciences, ON, Canada) and data analyzed with FACSDiva software Version 6.1.2 (BD Biosciences, ON, Canada). Absolute count numbers for cell populations were calculated using the BD Trucount™ tubes (BD Bioscience) according to manufacturer's instructions.

Cytokines Measurement in Lungs Homogenates {#S2-7}
------------------------------------------

Levels of TGF-β1 and CXCL12 (R&D Systems, Minneapolis, MN, USA) were determined by ELISA. Levels of IL-10, IL-17A, CCL5, TNFα, IL-6, and KC were determined using BD Cytometric Bead Array system (CBA Flex Set; BD Biosciences). Samples were analyzed with a BD FACS CANTO II flow cytometer and cytokine concentrations were evaluated with FCAP Array software (BD Biosciences). Results are expressed in pg/ml of lung homogenates.

CXCL12 and CCL5 Neutralization {#S2-8}
------------------------------

CXCL12 (SDF-1) was neutralized using anti-SDF-1 (clone K15C; Millipore, Massachussetts, NE, USA) antibody as previously described ([@B37]) and CCL5 was neutralized using anti-CCL5 (PeproTech, Rocky Hill, NJ, USA) antibody as described elsewhere ([@B38]). Neutralizing antibodies (32 μg/mouse) or IgG2 control isotype (32 μg/mouse) were intraperitoneally (i.p.) injected 24 h prior to IAV infection in WT mice. Thereafter, mice were treated daily with MDP and sacrificed at day 5 postinfection.

Immunofluorescence Analysis {#S2-9}
---------------------------

Lungs sections were fixed in paraformaldehyde for 15 min and then washed with PBS (3 × 15 min). Sections were incubated at room temperature in blocking solution containing PBS, 0.4% Triton X-100, 4% rat serum, and 0.5% bovine serum albumin for 20 min. Sections were then rinsed with PBS and stained overnight at 4°C with Ly6C-FITC (clone ER-MP 20; Abcam, Cambridge, UK) and Ly6G-A594 (clone 1A8; Biolegend, San Diego, CA, USA) antibodies. After extensive wash in PBS, lung sections were incubated with Hoechst 33342 for 15 min and mounted in Fluoromount medium for visualization under a confocal spinning disk microscope (Quorum wave FX, Quorum Technologies, Ontario, Canada).

Histological Analysis {#S2-10}
---------------------

Wild-type and *Nod2*^−/−^ mice were infected with IAV (50 PFU) and daily treated with placebo (0.9% p/v saline) or MDP (10 mg/kg). Lungs were harvested at day 5 postinfection and fixed in PFA (4%). Tissues were embedded in paraffin and lungs sections were stained with hematoxylin and eosin for histological analysis ([@B39]).

Statistical Analysis {#S2-11}
--------------------

All analyses were performed using Graph Pad Prism version 6.02 software (Graph Pad Software, San Diego, CA, USA). Statistical significance was set at *p* \< 0.05. Differences in groups were determined with a two-way analysis of variance (ANOVA) followed by a Tukey *post hoc* test or otherwise indicated.

Results {#S3}
=======

MDP Treatment Increases Levels of Treg Cells in Lungs of IAV-Infected Mice {#S3-1}
--------------------------------------------------------------------------

Excessive inflammation and structural damages to the lungs are consequences of infection by influenza virus (IAV) ([@B40]). Previous studies suggest that Treg cells can play a central role in immune homeostasis during viral infection ([@B13], [@B16]). Since we previously reported that administration of MDP to mice infected with IAV reduces lung inflammation ([@B32]), we first wanted to determine if such effects of MDP treatment could lead to the mobilization of Treg cells in lungs of IAV-infected mice. WT and NOD2-deficient mice (*Nod2^−/−^*) were infected with IAV and treated daily with MDP or placebo. At days 3, 5, and 7 postinfection (p.i.), Treg (CD4^+^ CD25^+^ FoxP3^+^) cells were assessed in lungs of IAV-infected mice. We observed in mice treated with MDP that number of Treg cells significantly increase at day 5 p.i. in lungs of IAV-infected animals to decline thereafter (Figures [1](#F1){ref-type="fig"}A,B). Similarly, lung viral loads were significantly reduced after 5 days of treatment with MDP (data not shown). Such effects of MDP treatment on Treg cells mobilization were strongly prevented in *Nod2*^−/−^ mice in lungs (Figure [1](#F1){ref-type="fig"}C). Comparable results were obtained when Treg frequencies were measured in blood of mice infected with IAV (data not shown).

![Muramyl dipeptide (MDP) treatment increases levels of regulatory T (Treg) cells in lungs of influenza A virus (IAV)-infected mice. **(A)** Representative gating strategy of Treg cells (CD4^+^ CD25^+^ FoxP3^+^) in lungs of naive and IAV-infected wild-type (WT) mice at day 5 postinfection. Mice were daily treated with placebo or MDP. Numbers in parentheses express the percentage (%) of Treg cells on CD4^+^ T population. Number of Treg cells in lungs of **(B)** WT and **(C)** *Nod2*^−/−^ mice infected with IAV and daily treated with placebo or MDP as measured by flow cytometry. Lungs samples were collected at days 3, 5, and 7 postinfection. **(D)** Representative gating strategy of Th17 cells (CD4^+^ IL-17A^+^) in lungs of naive and IAV-infected WT mice at day 5 postinfection. Numbers in parentheses express the percentage (%) of Th17 cells on CD4^+^ T population. Number of Th17 cells in lungs of **(E)** WT and **(F)** *Nod2^−/−^* mice infected with IAV and daily treated with placebo or MDP as measured by flow cytometry. Lungs samples were collected at indicated time post-infection. Results are presented as mean ± SEM of two independent experiments (*n* = 5 mice/groups). Differences in groups were determined with two-way analysis of variance followed by a Tukey *post hoc* test. \*\*\**p* \< 0.001, IAV-infected mice treated with placebo as compared to IAV-infected animals treated with MDP.](fimmu-09-00132-g001){#F1}

Mobilization and activation of Treg cells in the inflamed organ or tissue are closely related to the generation of Th17 cells. We have thus determined whether MDP treatment may affect this cell population during IAV infection. As expected, we observed that IAV infection induce the recruitment of Th17 cells into the lungs of mice. In contrast, in mice treated with MDP, a significant decrease of Th17 cell mobilization was observed in lungs of IAV-infected WT mice (Figures [1](#F1){ref-type="fig"}D,E). Again, effects of MDP on Th17 were abolished in *Nod2*^−/−^ mice (Figure [1](#F1){ref-type="fig"}F).

Excessive secretion of interleukin-17A (IL-17A) by Th17 cells may sustain neutrophil migration to the lungs following influenza infection ([@B20]--[@B22]), and therefore contribute to disease in severe influenza infection ([@B41]--[@B43]). Since our results show that administration of MDP leads to a decrease of Th17 cells mobilization to lungs of IAV-infected mice, we next wanted to determine whether neutrophils recruitment is also modulated by MDP treatment. WT mice were infected with IAV and treated daily with MDP or placebo. At days 3, 5, and 7 post-IAV infection, we assessed the levels of neutrophils in lung of mice (Figure [2](#F2){ref-type="fig"}A) as well as the concentration of IL-17A and KC, two mediators involved in neutrophil recruitment ([@B44]--[@B46]). IAV infection induces maximal recruitment of neutrophils in lungs of mice at 5 days postinfection, which correlates with increase of IL-17A and KC production (Figures [2](#F2){ref-type="fig"}B--D). In contrast, MDP treatment induces a significant decrease of neutrophils, IL-17A and KC production in lungs of IAV-infected animals at the same time point compared to the placebo groups. These results are supported by immunofluorescence analysis showing that MDP treatment decreases neutrophils (Ly6G^+^, Ly6C^+^) infiltration to the lungs of IAV-infected mice (Figure [2](#F2){ref-type="fig"}E). These first sets of experiments demonstrate that MDP treatment could induce recruitment of Treg cells to the lungs of IAV-infected mice but also favors the balance between Treg and Th17 cells in lungs of infected animals.

![Muramyl dipeptide (MDP) treatment reduces neutrophils migration to the lungs of influenza A virus (IAV)-infected mice. **(A)** Representative gating strategy of lungs neutrophils (CD45^+^, CD11b^+^, Ly6G^+^, Ly6C^+^) in wild-type (WT) naive mice. **(B)** Number of neutrophils was measured in lung tissues of IAV-infected mice treated with MDP or placebo at indicated time post-infection. Levels of **(C)** IL-17A and **(D)** KC were determined in lung homogenates of IAV-infected WT mice daily treated with placebo or MDP. Lungs were collected at days 3, 5, and 7 postinfection. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with two-way analysis of variance followed by a Tukey *post hoc* test. \*\*\**p* \< 0.001 and \*\*\*\**p* \< 0.0001, as compared to IAV-MDP-treated mice **(E)** Immunofluorescence analysis of lungs sections from IAV-infected mice daily treated with placebo or MDP. Lungs were extracted at day 5 postinfection and lung sections were stained with Hoechst (blue), Ly6C (green), and Ly6G (red) antibodies. Arrows show Ly6C^+^ and Ly6G^+^ neutrophils. Images are representative of one experiment (*n* = 4 mice/group).](fimmu-09-00132-g002){#F2}

CXCL12 and CCL5 Contribute to Treg Cell Trafficking following MDP Treatment {#S3-2}
---------------------------------------------------------------------------

Various chemokine receptors and integrins are involved in Treg cell trafficking. The CXCR4 receptor and its ligand CXCL12 appear to be crucial for bone marrow trafficking ([@B47]). CCR5 receptor was also found to be essential for recruitment of Treg cells to lymphoid tissues and organs including lungs ([@B48]). Since we observed that administration of MDP leads to the recruitment of Treg cells to the lungs of infected mice, we next wanted to determine whether CCL5, also known as RANTES, and CXCL12 chemokines may contribute to Treg cell mobilization after MDP treatment. We observed a marked increase of both CXCL12 and CCL5 at day 5 p.i. in lungs of mice following treatment with MDP compared to the control groups (Figures [3](#F3){ref-type="fig"}A,B). Importance of these chemokines in the mobilization of Treg cells to the lungs was demonstrated by the administration of anti-CXCL12 and anti-CCL5 neutralizing antibodies to mice prior infection and treatment with MDP. Indeed, numbers of recruited Tregs were found to significantly decrease by at least 60% in lungs of mice receiving neutralizing antibodies (Figures [3](#F3){ref-type="fig"}C,D). These results highlight the role of both CCL5 and CXCL12 in Treg cells migration induced by MDP.

![CXCL12 and CCL5 contribute to regulatory T (Treg) cell trafficking following muramyl dipeptide (MDP) treatment. Levels of **(A)** CXCL12 and **(B)** CCL5 production were measured in lung homogenates of influenza A virus (IAV)-infected wild-type (WT) mice daily treated with placebo or MDP. Lungs were collected at days 3, 4, 5, 6, and 7 postinfection. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with a two-way analysis of variance followed by a Tukey *post hoc* test. \**p* \< 0.05, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001 as compared to IAV-infected mice treated with placebo. **(C,D)** Number of Treg cells to the lungs was analyzed by flow cytometry in IAV-infected mice injected with **(C)** anti-CXCL12 or **(D)** anti-CCL5 neutralizing antibodies and daily treated with MDP or placebo. Neutralizing antibodies or IgG2 isotype control (32 μg/mice i.p.) was administered one day prior to IAV infection. Lungs were collected at day 5 postinfection. Results are presented as mean ± SEM of two independent experiments (*n* = 3 mice/groups). Differences in groups were determined with a Mann--Whitney test \**p* \< 0.05 when compared with indicated groups.](fimmu-09-00132-g003){#F3}

MDP Treatment Increases TGF-β and IL-10 Secretion in Lungs of IAV-Infected Mice {#S3-3}
-------------------------------------------------------------------------------

The importance of TGF-β and IL-10 in Treg-mediated suppression was demonstrated in several *in vivo* models ([@B49], [@B50]). Next, we determined whether the mobilization of Treg cells to the lung of infected mice treated with MDP correlates with the production of TGF-β and IL-10. Treatment with MDP leads to a gradual increase of TGF-β secretion in lungs of IAV-infected mice which was most pronounced at day 5 p.i. compared to the control groups. Production of IL-10 was mainly detectable at the same time point but rapidly decreased thereafter (Figures [4](#F4){ref-type="fig"}A,B). Similar results were obtained in sera of infected mice treated with MDP (data not shown). As expected, such effects of MDP treatment on TGF-β and IL-10 synthesis were abrogated in mice deficient for NOD2 receptor (Figures [4](#F4){ref-type="fig"}C,D).

![Muramyl dipeptide (MDP) treatment increases TGF-β and IL-10 secretion in lungs of influenza A virus (IAV)-infected mice. Levels of **(A,C)** TGF-β1 and **(B,D)** IL-10 were measured in lungs homogenates of IAV-infected wild-type (WT) (left panel) and *Nod2^−/−^* (right panels) mice daily treated with placebo or MDP. Lungs were collected at days 3, 5, and 7 postinfection. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with a two-way analysis of variance followed by a Tukey *post hoc* test. \*\*\**p* \< 0.001 and \*\*\*\**p* \< 0.0001 as compared to IAV-infected mice treated with placebo. Levels of **(E)** TNFα and **(F)** IL-6 were assessed in lung homogenates of IAV-infected WT mice daily treated with placebo or MDP. Lungs were harvested at day 5 postinfection. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with a Mann--Whitney test. \**p* \< 0.05 when compared with indicated groups. **(G)** Hematoxylin and eosin-stained lung sections from uninfected or IAV-infected WT and *Nod2*^−/−^ mice, treated daily with placebo or MDP. Lungs were harvested at day 5 postinfection. Images are representative of two independent experiments (*n* = 3 mice/group). a: example of alveolar and b: bronchiolar structure (original magnification 100×).](fimmu-09-00132-g004){#F4}

In line with these observations, treatment with MDP reduces production of inflammatory cytokines such as TNFα and IL-6 in lungs of infected mice (Figures [4](#F4){ref-type="fig"}E,F). Treatment with MDP also induced histological changes in lungs of infected mice which is characterized by a reduced interstitial leukocyte infiltrates (Figure [4](#F4){ref-type="fig"}G). These results suggest that MDP treatment may control excessive lung inflammation by regulating the production of TGF-β and IL-10 in mice infected with IAV.

Ly6C^low^ Blood Monocytes Contribute to Treg Cell Mobilization into the Lungs of IAV-Infected Mice Treated with MDP {#S3-4}
-------------------------------------------------------------------------------------------------------------------

We have previously reported that Ly6C^low^ patrolling monocytes are important for trafficking of Treg cells in a mouse model of arthritis and that *in vivo* administration of MDP increases levels of Ly6C^low^ monocytes in the blood of mice ([@B51], [@B52]). We wanted to determine whether Ly6C^low^ monocytes are essential to Treg recruitment in lung of mice during IAV infection. To achieve this goal, we have performed functional depletion of blood monocytes subsets using intravenous injection of clodronate-liposome. This approach has no effects on the number of alveolar macrophages. Kinetic of monocyte depletion experiment is presented in Figure [5](#F5){ref-type="fig"}A. In naive and IAV-infected mice treated with placebo, we observed that Ly6C^low^ patrolling monocytes gradually remerge at day 6 postclodronate and are fully restored by day 8 (Figure [5](#F5){ref-type="fig"}B). However, a more rapid emergence of Ly6C^low^ patrolling monocytes was observed following MDP treatment, starting to re-emerged at day 4 postclodronate administration due to the conversion of Ly6C^high^ into Ly6C^low^ monocytes following NOD2 triggering ([@B52]).

![Ly6C^low^ monocytes are involved in regulatory T (Treg) cells mobilization to lungs of influenza A virus (IAV)-infected mice. **(A)** Experimental design of blood monocyte depletion. Briefly, 1 day prior to IAV infection, mice were treated with clodronoate-liposome (200 µl i.v.) to deplete blood monocytes. **(B)** Gating strategy of blood monocytes subsets. After gating out the neutrophil cell population (CD45^+^/CD11b^+^/Ly6G^+^), monocytes were identified as CD45^+^, CD11b^+^, and CD115^+^. Monocyte subsets were further subdivided in three populations based on their expression level of Ly6C: Ly6C^high^, Ly6C^int^, and Ly6C^low^. Flow cytometry analysis of blood monocytes subsets was assessed at day 6 following PBS liposome administration and at days 4, 6, and 8 postclodronate liposome injection. **(C)** Treg and **(D)** Th17 cells numbers in lung tissues were measured by flow cytometry at days 1, 2, 4, 6, and 8 postclodronate administration in IAV-infected mice daily treated with placebo or muramyl dipeptide (MDP). Number of Ly6C^high^ and Ly6C^low^ monocytes (black curves) in the blood of IAV-infected mice treated with MDP is shown to illustrate monocytes subsets replenishment following clodronate liposome administration. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with a two-way analysis of variance followed by a Sidak *post hoc* test. \*\**p* \< 0.01, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001, IAV-infected mice treated with placebo (blue) compared to IAV-infected MDP-treated animals (red). Levels of CXCL12 **(E)**, CCL5 **(F)**, TGF-β1 **(G)**, and IL-10 **(H)** in lung homogenates were determined at days 4, 6, and 8 postclodronate administration in mice infected with IAV and daily treated with placebo or MDP. Arrows \[in panel **(E)**\] show the number of restored Ly6C^low^ monocytes in the blood of WT IAV-infected mice treated with MDP at days 4, 6, and 8 postclodronate liposome administration. This kinetic of Ly6C^low^ monocytes restoration is applicable to figure **(E--H)**. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001, when compared with IAV-infected mice treated with placebo.](fimmu-09-00132-g005){#F5}

In parallel, we assessed levels of Treg and Th17 cells mobilization to the lungs of IAV-infected mice at different times after administration of clodronate. We found that the number of Treg cells in mice treated with MDP transiently increase in lungs of infected animals after 6 days, when circulating Ly6C^low^ monocytes are fully restored (Figure [5](#F5){ref-type="fig"}C). Absence of Ly6C^low^ monocytes did not affect trafficking of Th17 cells to the lungs of IAV-infected mice treated with MDP (Figure [5](#F5){ref-type="fig"}D). In line with these data, optimal secretion of CXCL12 and CCL5 chemokines and of the suppressive TGF-β and IL-10 was also measured at day 6 postclodronate administration when Ly6C^low^ monocytes are present in the circulation (Figures [5](#F5){ref-type="fig"}E--H). These results suggest that MDP-induced Treg cell mobilization to the lung requires the presence of blood Ly6C^low^ monocytes.

To further confirm the contribution of Ly6C^low^ patrolling monocytes in mobilization of Tregs in lungs of infected mice treated with MDP, we delayed the replenishment of blood monocyte subsets by two consecutive administrations of clodronate-liposome as detailed in Figure [6](#F6){ref-type="fig"}A. In this case, patrolling monocytes only started reemerging in blood by day 10 postclodronate injection. We hypothesized that if we delay the renewal kinetic of Ly6C^low^ monocytes, the recruitment of Tregs to the lungs of mice should also be affected by the absence of this monocyte subset. In IAV-infected mice treated with a placebo, we confirmed that Tregs were detected by day 10 after clodronate administration when Ly6C^low^ monocytes begin to reemerge. We also confirmed that treatment of infected mice with MDP markedly increases the presence of Tregs to the lungs of mice (Figures [6](#F6){ref-type="fig"}B,C). This is consistent with our previous report showing that MDP treatment induces the conversion of blood Ly6C^high^ monocytes into Ly6C^low^ monocytes and consequently their number in the circulation ([@B52]). Presence of Tregs in lungs of mice also coincides with the optimal production of CXCL12, CCL5 and TGF-β in lungs of IAV-infected mice treated with MDP compared to mice treated with a placebo (Figures [6](#F6){ref-type="fig"}D--F). Thus, these results indicate that the presence of Ly6C^low^ monocytes is essential to MDP to stimulate Treg recruitment to the lungs of mice.

![Sustained depletion of Ly6C^low^ monocytes delays muramyl dipeptide (MDP)-induced regulatory T (Treg) recruitment in lungs of influenza A virus (IAV)-infected mice. **(A)** Experimental design of blood monocyte depletion. **(B)** Monocytes subsets quantification was measured at days 6 (left panels) and 10 (left panels) postclodronate liposome administration in IAV-infected mice daily treated with placebo or MDP. Flow cytometry analysis show monocyte subset replenishment at indicated times. In parallel, Treg cells renewal is also monitored at days 6 (right panels) and 10 (right panels) postclodronate liposome administration in IAV-infected mice daily treated with placebo or MDP. Numbers in parentheses express the percentage (%) of Treg cells on CD4^+^ T population. **(C)** Absolute numbers of lungs Tregs cells were measured at indicated time following clodronate liposome administration. Arrows show the number of blood Ly6C^low^ monocytes detected in wild-type IAV-infected mice treated with MDP at days 6, 8, 10, and 12 postclodronate liposome administration. This kinetic of Ly6C^low^ monocytes restoration applies to figure **(C--F)**. Levels of **(D)** CXCL12, **(E)** CCL5, and **(F)** TGF-β1 in lung homogenates were measured at days 6, 8, 10, and 12 postclodronate administration in mice infected with IAV and daily treated with placebo or MDP. Results are presented as mean ± SEM of two independent experiments (*n* = 4 mice/groups). Differences in groups were determined with a two-way analysis of variance followed by a Sidak *post hoc* test. \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001, when compared with IAV-infected animals treated with placebo.](fimmu-09-00132-g006){#F6}

Discussion {#S4}
==========

While NOD2 receptor is recognized as a natural sensor of microbial fragments, its role in the regulation of inflammatory response remain to be explored. In a previous work, we have shown that NOD2 triggering by MDP treatment improves mice pulmonary function during IAV infection, suggesting that NOD2 pathway may contribute to regulate lung inflammation ([@B32]). In the present study, we demonstrate that Treg cells are associated with NOD2-mediated signals that participate to regulate lung inflammation in IAV-infected mice.

We found that triggering of NOD2 can provide physiological signals leading to the emergence of Treg cells. However, although the mechanism(s) that control such an emergence of Treg cells remain to be solved, we believe that secretion of TGF-β induced after NOD2 triggering plays a significant role in this process. It is known that TGF-β is a critical factor regulating Treg cell development by converting naive CD4^+^ T cells into CD4^+^ CD25^+^ T cells in the periphery and by inducing expression of FoxP3 in these cells ([@B12], [@B53]--[@B56]). Our results show that MDP treatment significantly increases Treg cells mobilization in lungs of IAV-infected mice which coincide with an increased production of TGF-β, a cytokine intimately associated with Treg function. Although various cell populations can produce TGF-β, we believe that Ly6C^low^ monocytes are a major source of TGF-β, as we have previously proposed ([@B51]). The reduction of inflammatory mediators such as TNFα and IL-6 along with an increase of both TGF-β production and Treg cell levels in lungs of mice treated with MDP are also consistent with an improved tissue integrity. We also observed that emergence of CD4^+^ Tregs in lungs of infected mice treated with MDP is transient, e.g., their numbers rapidly decrease when lung viral loads are reduced after treatment and when tissue integrity is restored. Such a kinetic of Treg trafficking was seen in other models of inflammation ([@B57], [@B58]). It is thus plausible that the observed rapid decrease of Treg cells could be related to the duration of the infection. Indeed, it appears likely that CD4^+^ Tregs could play a more consistent effect in response to chronic or persistent infection in which ample time is available for Treg activation and mobilization ([@B13], [@B59], [@B60]). An optimal production of IL-10 in lungs of IAV-infected mice treated with MDP was also found to coincide with the kinetic of Treg cell mobilization and the resolution of phase of infection. While various immune effector cells can release IL-10, this mediator can be markedly produced by CD4^+^ Treg cells following MDP treatment given the known connection between CD4^+^ Treg cells and IL-10 in the suppression of Th17 cells and in promoting the formation of CD8^+^ T cells during viral infection ([@B55], [@B61]--[@B63]). In our model, we believe that CD4^+^ Treg cells could play a central role in protecting host following NOD2 triggering by MDP, a process requiring the production of TGF-β. Although we demonstrated that activation of NOD2 receptor initiates the migration of CD4^+^ Treg cells to the lungs during IAV infection, the consequences of NOD2 triggering on CD8^+^ Treg cells remain to be investigate since CD8^+^ Tregs can also be induced during IAV infection ([@B64]).

In addition to the increased number of CD4^+^ Treg to the lung during IAV infection, MDP treatment was found to reduce Th17 cells mobilization which correlates with a decrease of neutrophil levels. We hypothesized that neutrophils infiltrate the injured lung in the early phase following infection with IAV and triggered the first wave of host defense against infection. Thereafter, Treg cells are mobilized to the lungs to attenuate excessive inflammation. NOD2 triggering may thus favor the Treg/Th17 immune balance and consequently the lung homeostasis. The precise mechanisms underlying the control of Treg/Th17 immune balance remain to be clarified.

We have previously reported that *in vivo* stimulation of NOD2 with MDP induces the emergence of circulating Ly6C^low^ patrolling monocytes ([@B52]) and also that the presence of Ly6C^low^ monocytes was required for Treg cell recruitment in a serum transfer-induced arthritis mice model ([@B51]). When performing functional depletion of blood monocytes, we showed that both Treg cell mobilization and restoration of Ly6C^low^ monocytes occurs simultaneously, a process associated with the reduction of inflammation in inflamed joints of arthritic mice. In IAV infection model, mobilization of Treg cells in lungs of mice also requires the presence of Ly6C^low^ monocytes. In this regard, these cellular populations appear to be crucial in NOD2-related signals to exert a control on IAV-induced lung inflammation and in a chronic inflammatory environment ([@B42], [@B43]). Furthermore, TGF-β release occurs once Ly6C^low^ monocytes are restored after monocyte depletion and when Tregs increase is detected in lungs of treated mice ([@B51]). We thus propose that treatment with MDP may promote physiological signals involving TGF-β production by mononuclear phagocytes, predominantly Ly6C^low^ monocytes, which in turn facilitate the conversion of T cells into CD4^+^ Tregs during IAV infection. Together, this study underlines the contribution of NOD2 in the control of lung inflammation during IAV infection through the mobilization of Treg cells.
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